 Home > Medical News > Latest Medical News > Luye Pharmaceutical's innovative compound liposome formulation completes the first patient enrollment in Phase I clinical trials

Luye Pharmaceutical's innovative compound liposome formulation completes the first patient enrollment in Phase I clinical trials

 Last Update: 2021-05-22
 Source: Internet
 Author: User

Tags

stitch side pain

cancer associated fibroblasts

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 29, Luye Pharmaceutical Group announced that its self-developed innovative anti-tumor preparation-Irinotecan Hydrochloride Liposome Injection (LY01616) has completed the first phase I clinical patient enrollment.

LY01616 can co-encapsulate irinotecan and fluorouridine in compound liposomes in a specific synergistic ratio.

According to the National Comprehensive Cancer Network (NCCN) Colorectal Cancer Diagnosis and Treatment Guidelines and the Chinese Society of Clinical Oncology (CSCO) Colorectal Cancer Diagnosis and Treatment Guidelines, the combination chemotherapy of irinotecan and fluorouracil is one of the first options for advanced colorectal cancer.

·Afteririnotecan and fluorouracil are combined as a conventional injection, the ratio of the two in the body changes rapidly, which affects the efficacy of combined chemotherapy and makes it difficult to exert the best synergistic anti-tumor effect;

·The infusion time of this treatment plan is as long as 46-48 hours, which is easy to increase the possibility of adverse reactions and other complications.

In response to the above-mentioned clinical pain points that need to be resolved, LY01616 co-encapsulated irinotecan hydrochloride and fluorouridine in an innovative liposome preparation.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.